In its Fiscal year (FY) 2011, FDA approved 35 new molecular entities (NMEs). Rare or so-called “orphan” diseases (affects <200,000 persons), which may have previously had few or no drug treatments available, are addressed by 10 of the newly approved drugs in FY 2011, according to Drug Topics, March 2012. For a summary of the 17 most notable NMEs, as published in Drug Topics, click here . For more information on 7th Annual Rare Disease and Orphan Drug Leadership Congress, July 18-19, 2012 in Philadelphia, PA click here.
The Latest FDA Drug Approvals
April 9, 2012